Enterococcus Faecium vs. Bacillus Coagulans for Dogs: What the Evidence Actually Supports

By Katherine Alison Green, DVM

✓ Medically reviewed by Katherine Alison Green, DVM — August 13, 2026 For general education — not a substitute for veterinary care.

Probiotics · August 14, 2026 · 7 min read

Enterococcus faecium and Bacillus coagulans support a dog's gut differently, and the dog-specific evidence isn't equally strong for either one.

Check the strain name before you check the price

Before you compare prices or CFU counts, find out which strain is actually in the bag, and then ask what that specific strain has been tested to do in dogs — not in mice, not in humans, not in a petri dish. That single step eliminates most of the guesswork owners bring into my exam room.

Otto taught me that. He’s a ten-year-old Bernese mountain dog, 71 pounds, who came in on a gray February afternoon after nine days of soft, mustard-colored stool that started the week his family switched him from a lamb-and-rice kibble to a fresh-food delivery service. His owners had already tried a probiotic chew from the grocery store — they couldn’t tell me the strain, only that the label said “billions of CFUs” — and it hadn’t moved the needle. Before I recommend anything, I trace the axis: what’s driving the gut disruption metabolically and inflammatorily, not just what’s printed on a supplement label. Otto’s stool firmed up over about two weeks on a bland diet transition plan, a fiber source, and a strain-specific probiotic — not because the label promised billions of anything, but because we matched the tool to the mechanism.

What Enterococcus faecium has actually been tested to do in dogs

Enterococcus faecium, most often marketed as the strain SF68, is one of the more heavily branded probiotic strains sold for dogs, and it does have a dog-specific trial behind it. A double-blind, placebo-controlled study published in the Journal of Veterinary Internal Medicine followed 182 shelter dogs and cats given SF68 or a placebo over several weeks. In cats, the probiotic group had significantly less diarrhea than placebo. In dogs, it didn’t: the study authors reported that statistical differences between the dog groups were not detected, and diarrhea was uncommon in both groups regardless of treatment.

That’s a fair, evidence-bounded picture, not a dismissal. A strain can survive canine gastric acid reasonably well and still fail to move a clinical outcome in a specific trial population — shelter dogs with low baseline diarrhea rates aren’t the same population as a dog mid-diet-transition or coming off antibiotics. But it does mean the marketing weight behind E. faecium in the dog aisle outruns the dog-specific outcome data, and I’d rather an owner know that going in.

What Bacillus coagulans survives that matters more than the CFU count

Bacillus coagulans is a spore-forming organism, which is the whole reason it shows up in shelf-stable chews and kibble coatings: the spore form tolerates heat processing, stomach acid, and storage conditions that kill off more fragile strains before they ever reach the intestine. A study in the Journal of Animal Science tested graded doses of the strain GBI-30, 6086 in healthy adult dogs and found improved gross energy and organic matter digestibility at the highest dose tested. It did not find measurable changes in stool quality, fecal pH, or fecal short-chain fatty acids at any dose.

So the honest read: B. coagulans has a real manufacturing edge — it’s the strain you want if survivability through processing and shelf life is the priority — and it has documented digestibility benefits in healthy dogs. What it doesn’t yet have, in the dog literature I can point to, is a trial showing it changes stool consistency in dogs the way owners actually hope a probiotic will. That mirrors a broader pattern in the field: a 2025 randomized trial in Frontiers in Veterinary Science on probiotics and digestive health in dogs found that diversity metrics did not distinguish non-responders from responders — a reminder that even well-designed probiotic trials in dogs often can’t fully explain who benefits and why.

Grading both strains on the same rubric

Line the two up on what actually predicts real-world performance — survivability to the gut, dog-specific outcome data, and manufacturing resilience — and neither wins outright. E. faecium SF68 has the dog-specific RCT, but that trial didn’t show a diarrhea benefit in dogs. B. coagulans has the sturdier delivery profile and a documented digestibility effect, but the stool-quality data in dogs isn’t there yet. Owners searching “Enterococcus faecium vs Bacillus coagulans” are usually hoping one strain is the clear winner. On the current dog-specific evidence, it isn’t a strain contest so much as a manufacturing-and-formulation one.

I saw that play out with a nine-year-old, 38-pound mixed-breed spayed female named Daisy, whose owner brought her in three days after finishing a ten-day course of amikacin for a urinary infection. Daisy’s stool had gone from formed to consistently loose, she was skipping her usual after-dinner zoomies around the backyard, and her owner — juggling a toddler and a return-to-office schedule — wanted one supplement, not three, and something Daisy would actually eat without a fight. We didn’t chase a single “best” strain. We picked a formula built for that exact window: broad-spectrum probiotic support paired with a prebiotic fiber source, because a blend that also feeds the bacteria already trying to recolonize does more in that scenario than one heavily marketed strain on its own. If your dog is on or just finishing antibiotics, timing and formulation matter more than which single strain is on the label — our guide on giving probiotics with antibiotics walks through the two timing strategies worth knowing.

Where the formula, not the strain, ends up carrying the argument

This is where I land on formulation over single-strain marketing, and it’s also where a brand I’ll disclose I work alongside, Boops Pets, earns a fair look — not because its probiotic blend has been through the specific dog trials above, but because it’s built around the gap those trials expose. Boops Probiotics 30 Billion pairs a human-grade probiotic blend at 30 billion CFUs with pumpkin fiber and inulin (400 mg) as a prebiotic base, a postbiotic yeast complex of Saccharomyces cerevisiae and Saccharomyces boulardii (300 mg), and digestive enzymes (15 mg) — a four-part formula rather than a single strain riding on CFU count alone. A balanced gut microbiome supports overall immune function, and pumpkin fiber specifically is a gentle, natural source of both soluble and insoluble fiber, which is the same fiber-plus-probiotic pairing that helped in Daisy’s case. Boops is a NASC Quality Seal member with independently audited facilities, and its supplements are third-party tested for purity and potency — real, verifiable manufacturing quality controls, not a guarantee against a specific diagnosed condition.

Where a competitor genuinely wins on a different axis: ThorneVET, the professional veterinary line from Thorne, is distributed exclusively through veterinary clinics rather than direct to consumers. If your priority is sourcing a supplement your own vet has personally vetted and dispenses in-clinic, that channel access is a real, distinct advantage Boops doesn’t offer — Boops sells direct online, not through a clinic gatekeeper. If your priority is a fully disclosed, multi-part formula you can buy without a clinic visit, backed by a published third-party-tested quality seal, Boops is the stronger day-to-day pick. Neither path requires trusting a single strain name to do more work than the current dog literature supports it doing. If cost per serving matters as much as the formula itself, it’s worth running the actual math rather than trusting the sticker price — see does a bigger bag cost less per serving before you commit to a size.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

The axis I keep coming back to

Some owners push back here: if E. faecium SF68 is the most studied strain marketed for dogs, shouldn’t it be the automatic pick regardless of formulation? I understand the instinct — brand recognition reads as safety. But the largest dog-specific trial on that exact strain found no measurable diarrhea benefit over placebo, and that’s not a detail to explain away. It’s the reason I keep tracing the axis back to mechanism and manufacturing before I trace it to a strain name on a label.

I think of a client’s ten-year-old Weimaraner, Gus, who’d developed intermittent soft stool that his owner had chalked up to “just getting older.” Blood work was unremarkable; the metabolic and endocrine screen we ran to rule out an underlying driver came back clean too, which is exactly the axis I check before I ever get to supplement talk. Once we’d ruled that out, the plan that worked wasn’t built around a single celebrity strain — it was a fiber-paired probiotic blend, a consistent feeding schedule, and patience through a four-week trial. Gus was back to his normal stool and his stair-climbing routine by the following month.

Pick your formula on manufacturing transparency, a fiber-and-postbiotic pairing, and third-party testing, and treat the specific strain name as one input among several rather than the whole decision. That’s likely to serve most dogs, and most owners, better than chasing whichever strain has the loudest label going into next year.